Androgens and menopause: more fuel for the fire.
Shulman
Lee P
LP
D000728:Androgens / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage; D015986:Confounding Factors, Epidemiologic; D003511:Cyclohexanols / Q000008:administration & dosage; D003863:Depression / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D015914:Estrogen Replacement Therapy / Q000379:methods; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D006801:Humans; D008389:Marketing of Health Services; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008593:Menopause / Q000097:blood / Q000523:psychology; D008777:Methyltestosterone / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D013739:Testosterone / Q000172:deficiency*; D000069470:Venlafaxine Hydrochloride
D000728:Androgens; D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D004966:Estrogens, Conjugated (USP); D013739:Testosterone; D000069470:Venlafaxine Hydrochloride; D008525:Medroxyprogesterone; D008777:Methyltestosterone